Journal Logo

PRESCRIPTION PATTERNS AND OUTCOMES OF FIRST-LINE THERAPY FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA REAL-LIFE PATIENTS ACCORDING TO AGE: A RETROSPECTIVE ANALYSIS OF THE 2012-2016 PERIOD

PB2144

Cejalvo, M. J.1; Sureda, A.2; González, E.3; Vázquez-Álvarez, J.4; García, R.5; Ramírez, Á.6; Pérez-Persona, E.7; Abella, E.8; Garzón, S.9; García, A.10; Jarque, I.11; González, M. S.12; Sampol, A.13; Motlló, C.14; Martí, J. M.15; Alcalá, M.16; Duro, R.17; González, Y.18; Sastre, J. L.19; Sarrà, J.20; Lostaunau, G.21; López, R.21; de la Rubia, J.1

doi: 10.1097/01.HS9.0000567060.69181.a9
Publication Only: Myeloma and other monoclonal gammopathies - Clinical
Free

1Hospital Universitario Doctor Peset, Valencia

2Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona

3Hospital de Cabueñes, Gijón

4Hospital Álvaro Cunqueiro, Vigo

5Hospital Virgen de la Victoria, Málaga

6Hospital Central de Asturias, Oviedo

7Hospital Universitario de Alava, Vitoria-Gasteiz

8Hospital del Mar, Barcelona

9Hospital de Jerez, Jerez de la frontera

10Hospital Arnau de Vilanova, Lleida

11Hospital Universitario y Politécnico La Fe, Valencia

12Hospital de Santiago, Santiago de Compostela

13Hospital Son Espases, Palma de Mallorca

14Fundació Althaia, Barcelona

15Hospital Mútua de Terrassa, Terrassa

16Hospital Universitario Carlos Haya, Málaga

17Hospital Universitario Virgen de la Macarena, Sevilla

18Hospital Universitario de Girona Doctor Josep Trueta, Girona

19Complejo Hospitalario Universitario de Ourense, Ourense

20Hospital Universitario Joan XXIII, Tarragona

21Celgene, S.L.U., Madrid, Spain

Back to Top | Article Outline

Background:

Multiple myeloma (MM) affects elderly individuals with two-thirds of patients aged >65 years at diagnosis, 35% ≥75 and 10% ≥80. In general, routine clinical practice is based on the results of large, multicenter, randomized clinical trials. However, despite efforts from cooperative groups, patients enrolled in trials are generally younger and presumably healthier than the typical older patient with MM

Back to Top | Article Outline

Aims:

To describe prescription patterns for first-line treatment of non-transplant eligible MM patients in the setting of real-life practice and to analyze treatment outcome according to patients' age

Back to Top | Article Outline

Methods

Retrospective analysis of newly diagnosed MM patients not eligible for transplantation, who started anti-myeloma treatment between 2012-2016 in 20 Spanish hospitals. Variables collected included patients' characteristics at diagnosis (ECOG, laboratory parameters, ISS, and cytogenetics/fluorescent in situ hybridization), characteristics of first-line treatment, overall survival (OS), progression-free survival (PFS), and overall response rate (ORR), defined as partial response or better

Back to Top | Article Outline

Results:

The retrospective cohort included 421 patients with a median age of 76 years (41-90); 203 (49%), 106 (26%), and 104 (25%) were ≤75, 76-80, and >80 years old, respectively; 28 (12%) had ECOG >2. ISS staging was I, II, III in 57 (18%), 93 (30%), and 160 (52%) patients, respectively; 73 (25%) patients had high-risk cytogenetics. The most frequently prescribed regimen was VMP (208 patients), followed by other bortezomib-based regimens (130 patients) (Table 1). Overall, median treatment duration was 6 months (95%CI 5-7) and the ORR was 74% (for patients ≤75, 75-80, and >80 years old: 76%, 80%, and 62%; P = 0.025). Overall, 188 (45%) patients required a dose adjustment and 225 (81%) started second-line treatment. Median OS and PFS were 32 (95% CI 29-37) and 15 months (95% CI 14-17), respectively. OS and PFS of patients ≤75, 75-80, and >80 years old were 44 and 16 months, 28 and 17 months, and 23 and 12 months (P < 0.01 for age-group differences in both OS and PFS).

Figure

Figure

Back to Top | Article Outline

Summary/Conclusion:

In real-life practice, there is high variability in treatment regimens, being bortezomib-based the most frequently prescribed regimens in the study period. Besides the clinical characteristics of MM patients, age influenced survival in our cohort of real-life patients, suggesting that treatment choice for elderly patients should be based on a specific pre-treatment assessment of risks and benefits.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.